Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

In this article, we will look at the 12 Best Undervalued Stocks to Invest In Right Now. On March 3, Katie Stockton, Fairlead ...

Ninety-five percent of adolescent athletes with lumbar spine stress fractures recovered without surgery, according to research from New York City-based Hospital for Special Surgery presented at the ...

Navepegritide is indicated for those ages 2 and older with open epiphyses ...